Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending October 25, 2013. The report details a specific share repurchase transaction executed in accordance with shareholder authority granted at the Annual General Meeting on May 1, 2013.
Key Financial Metrics
The filing does not provide data on revenue, profit, cash flow, margins, debt, or liquidity. It focuses exclusively on capital structure and share buyback activity.
- Shares Purchased: 310,000 Ordinary Shares of 25 pence each.
- Purchase Date: October 25, 2013.
- Price Range: Highest price paid was 1,619.50 pence per share; lowest price paid was 1,600.00 pence per share.
- Treasury Holdings (Settled): 507,352,912 shares (9.45% of total issued share capital).
- Treasury Holdings (Including Unsettled): 507,662,912 shares (10.44% of total voting rights).
- Shares in Issue (Excluding Treasury): 4,861,448,939 shares.
Material Changes
The primary material change is the reduction of outstanding shares through the purchase of 310,000 shares for Treasury. Consequently, the percentage of total voting rights held in Treasury increased to 10.44% when including unsettled purchases.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It is a compliance disclosure confirming conformity with the Financial Conduct Authority's Disclosure and Transparency Rules.
Investor Verification Checklist
- Verify the total number of shares held in Treasury (507,352,912 settled) against the company's latest capitalization table.
- Confirm the calculation of total voting rights (10.44% held in Treasury including unsettled shares).
- Check the number of shares in issue (4,861,448,939) to ensure accurate denominator usage for shareholder notification thresholds under FCA rules.
- Note that this filing does not contain operational or financial performance data for the period.